Previous 10 | Next 10 |
2023-08-11 14:55:42 ET BofA Securities has initiated coverage of Kura Oncology ( NASDAQ: KURA ) with a buy rating, commenting that it sees the stock as undervalued given the long-term revenue potential of its lead drug candidate ziftomenib, which is being developed as a treatment fo...
2023-08-05 21:08:08 ET Syndax Pharmaceuticals, Inc. (SNDX) Q2 2023 Earnings Conference Call August 3, 2023, 4:30 pm ET Company Participants Sharon Klahre - Head, IR Michael Metzger - CEO Neil Gallagher - President & Head, R&D Keith Goldan - CFO Pe...
2023-08-03 16:52:53 ET Syndax Pharmaceuticals press release ( NASDAQ: SNDX ): Q2 GAAP EPS of -$0.64 beats by $0.09 . As of June 30, 2023, Syndax had cash, cash equivalents, and short- and long-term investments of $418.3 million and 69.7 million common shares and p...
Syndax Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Clinical and Business Update PR Newswire – Announced positive topline results from the pivotal AGAVE-201 trial of axatilimab in cGVHD – – Topline data from the pivota...
Syndax to Announce Second Quarter 2023 Financial Results and Host Conference Call and Webcast on August 3, 2023 PR Newswire WALTHAM, Mass. , July 25, 2023 /PRNewswire/ -- Syndax Pharmaceuticals (Nasdaq: SNDX), a clinical-stage biopharmaceutical company developing...
2023-07-24 08:37:45 ET AMC Entertainment Holdings ( AMC ) +45% give jolt to summer box office. POSCO Holdings ( PKX ) +17% . Sculptor Capital Management ( SCU ) +16% to acquire Sculptor Capital for $639M. Koss Corporation ( KOSS ) +14% ...
Syndax and Incyte Announce Positive Topline Results from the Pivotal AGAVE-201 Trial of Axatilimab in Chronic Graft-Versus-Host Disease PR Newswire – Trial met its primary endpoint across all cohorts with an overall response rate (ORR) of 74% at a dose of 0.3 mg/kg admi...
2023-07-09 18:15:18 ET Acumen Pharmaceuticals ( NASDAQ: ABOS ), Establishment Labs ( NASDAQ: ESTA ), Arcus Biosciences ( NYSE: RCUS ) and BridgeBio Pharma ( NASDAQ: BBIO ) are four of BTIG's top picks for small and mid-cap healthcare stocks going into the lat...
2023-06-08 08:29:28 ET Summary Syndax Pharmaceuticals offers a unique investment opportunity in precision oncology with a strong financial standing and commitment to research and development. The company's drug pipeline includes revumenib, axatilimab, and entinostat, which show po...
2023-05-08 22:53:03 ET Syndax Pharmaceuticals, Inc. (SNDX) Q1 2023 Earnings Conference Call May 08, 2023, 04:30 PM ET Company Participants Sharon Klahre - Head, Investor Relations Michael Metzger - Chief Executive Officer Neil Gallagher - President and Head of R&...
News, Short Squeeze, Breakout and More Instantly...
Syndax Pharmaceuticals Inc. Company Name:
SNDX Stock Symbol:
NASDAQ Market:
Syndax Pharmaceuticals Inc. Website:
PALM BEACH, Fla., June 17, 2024 (GLOBE NEWSWIRE) -- FN Media Group News Commentary - Acute Myeloid Leukemia (AML) is a type of cancer that affects the blood and bone marrow. It is characterized by the rapid growth of abnormal myeloid cells, which are immature blood cells that normally...
Syndax Presents Updated Positive Data from BEAT AML and AUGMENT-102 Phase 1/2 Combination Trials of Revumenib in Patients with Acute Leukemias at EHA 2024 Congress PR Newswire - Data continue to support revumenib's potential to enhance current standard of care agents - ...
BOSTON, June 10, 2024 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: “PYXS”), a clinical stage company focused on developing next generation therapeutics to target difficult-to-treat cancers, today announced the appointment of Michael A. Metzger to its Board of Directors, effecti...